l carnitina mas cla + 250GRS BEASTIC CLA + L-CARNITINA |
Description
2025;47:e00512
Harm Reduct J 2024, 21, 119, doi:10.1186/s12954-024-01038-2
Isenberg DA, Furie RA, Jones N et al (2021) Efficacy, safety, and pharmacodynamic effects of the Brutons tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial
About this article Cite this article Haidary, M., Akbari, E., Hossaini, D
